Hong Sang

Array ( [id] => 13383333 [patent_doc_number] => 20180243208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => AUGMENTATION OF PERSONALIZED TUMOR SPECIFIC ADAPTIVE IMMUNITY THROUGH EXTRACORPOREAL REMOVAL OF IMMUNE BLOCKING FACTORS [patent_app_type] => utility [patent_app_number] => 15/908620 [patent_app_country] => US [patent_app_date] => 2018-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14263 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15908620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13826617 [patent_doc_number] => 20190016793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => Albumin binding domain fusion proteins [patent_app_type] => utility [patent_app_number] => 15/932387 [patent_app_country] => US [patent_app_date] => 2018-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22381 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15932387 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13837317 [patent_doc_number] => 20190022143 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => COMPOSITIONS AND METHODS FOR INCREASING MESENCHYMAL STROMAL CELL MIGRATION TO TUMORS [patent_app_type] => utility [patent_app_number] => 15/892680 [patent_app_country] => US [patent_app_date] => 2018-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14490 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15892680 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13371951 [patent_doc_number] => 20180237516 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => ANTIBODIES THAT RECOGNIZE IAPP [patent_app_type] => utility [patent_app_number] => 15/893395 [patent_app_country] => US [patent_app_date] => 2018-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20921 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15893395 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13493133 [patent_doc_number] => 20180298109 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-18 [patent_title] => POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS [patent_app_type] => utility [patent_app_number] => 15/882240 [patent_app_country] => US [patent_app_date] => 2018-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 117864 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15882240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16925306 [patent_doc_number] => 11046768 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-29 [patent_title] => Bispecific HER2 and CD3 binding molecules [patent_app_type] => utility [patent_app_number] => 15/881042 [patent_app_country] => US [patent_app_date] => 2018-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 49 [patent_figures_cnt] => 90 [patent_no_of_words] => 55822 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15881042 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13522077 [patent_doc_number] => 20180312581 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => Method For Making Heteromultimeric Molecules [patent_app_type] => utility [patent_app_number] => 15/879113 [patent_app_country] => US [patent_app_date] => 2018-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21007 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15879113 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13337275 [patent_doc_number] => 20180220176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-02 [patent_title] => Means and Methods for Detecting Methylated DNA [patent_app_type] => utility [patent_app_number] => 15/876844 [patent_app_country] => US [patent_app_date] => 2018-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24259 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15876844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16474929 [patent_doc_number] => 10849849 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-01 [patent_title] => Subcutaneous HER2 antibody formulations [patent_app_type] => utility [patent_app_number] => 15/872648 [patent_app_country] => US [patent_app_date] => 2018-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 35 [patent_no_of_words] => 31277 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15872648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13410299 [patent_doc_number] => 20180256692 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => VACCINE THERAPY FOR TREATMENT OF ENDOMETRIAL AND OVARIAN CANCER [patent_app_type] => utility [patent_app_number] => 15/872626 [patent_app_country] => US [patent_app_date] => 2018-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11577 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15872626 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13357331 [patent_doc_number] => 20180230205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => ANTIBODIES TO ENDOPLASMIN AND THEIR USE [patent_app_type] => utility [patent_app_number] => 15/870532 [patent_app_country] => US [patent_app_date] => 2018-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31955 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15870532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13314217 [patent_doc_number] => 20180208645 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => Compositions and Methods for Treating Cancer with Anti-Mesothelin Immunotherapy [patent_app_type] => utility [patent_app_number] => 15/866222 [patent_app_country] => US [patent_app_date] => 2018-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28361 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15866222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18216476 [patent_doc_number] => 11591398 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-28 [patent_title] => Single domain antibodies to programmed cell death protein 1 (PD-1) [patent_app_type] => utility [patent_app_number] => 16/475597 [patent_app_country] => US [patent_app_date] => 2018-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 11 [patent_no_of_words] => 25342 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16475597 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19624128 [patent_doc_number] => 12162932 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-10 [patent_title] => Combined treatment with Netrin-1 interfering drug and immune checkpoint inhibitors drugs [patent_app_type] => utility [patent_app_number] => 16/476239 [patent_app_country] => US [patent_app_date] => 2018-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 11366 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 172 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16476239 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13311395 [patent_doc_number] => 20180207234 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => INHIBITION OF CANCER GROWTH AND METASTASIS [patent_app_type] => utility [patent_app_number] => 15/863386 [patent_app_country] => US [patent_app_date] => 2018-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23555 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15863386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14534527 [patent_doc_number] => 20190202885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => TauT (taurine transporter) peptide cancer vaccine [patent_app_type] => utility [patent_app_number] => 15/858880 [patent_app_country] => US [patent_app_date] => 2017-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9635 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15858880 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17393400 [patent_doc_number] => 11242402 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => ADAM9-binding molecules, and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/471449 [patent_app_country] => US [patent_app_date] => 2017-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 23 [patent_no_of_words] => 38940 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16471449 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12912637 [patent_doc_number] => 20180196055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => PD-L1 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/851513 [patent_app_country] => US [patent_app_date] => 2017-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19736 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 165 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15851513 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12866359 [patent_doc_number] => 20180180628 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => METHODS OF TREATING CANCER BY IDENTIFICATION OF PATIENTS SENSITIVE TO FGFR INHIBITOR THERAPY [patent_app_type] => utility [patent_app_number] => 15/833671 [patent_app_country] => US [patent_app_date] => 2017-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6145 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15833671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13119477 [patent_doc_number] => 10078090 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-18 [patent_title] => SAB as a biomarker for degenerative diseases and therapeutic sensitivity in cancers [patent_app_type] => utility [patent_app_number] => 15/828842 [patent_app_country] => US [patent_app_date] => 2017-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 38 [patent_no_of_words] => 16273 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15828842 [rel_patent_id] =>[rel_patent_doc_number] =>)